Association between pain outcomes and race and opioid treatment: Retrospective cohort study of Veterans by Burgess, Diana J. et al.
13
JRRD Volume 53, Number 1, 2016Pages 13–24
Association between pain outcomes and race and opioid treatment: 
Retrospective cohort study of Veterans
Diana J. Burgess, PhD;1–2* Amy A. Gravely, MA;1 David B. Nelson, PhD;1–2 Matthew J. Bair, MD, MS;3 Robert 
D. Kerns, PhD;4 Diana M. Higgins, PhD;4 Melissa M. Farmer, PhD;5 Melissa R. Partin, PhD1–2
1Center for Chronic Disease Outcomes Research, Minneapolis Department of Veterans Affairs (VA) Health Care Sys-
tem, Minneapolis, MN; 2Department of Medicine, University of Minnesota Medical School, Minneapolis, MN; 3Center 
for Health Information and Communication, VA Health Services Research & Development, Richard L. Roudebush VA 
Medical Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; and Regenstrief Institute Inc, 
Indianapolis, IN; 4VA Connecticut Healthcare System, West Haven, CT; and Yale School of Medicine, New Haven, CT; 
5VA Health Services Research and Development Service, Center for the Study of Healthcare Innovation, Implementation 
and Policy, VA Greater Los Angeles Healthcare System, Sepulveda, CA
Abstract—We examined whether pain outcomes (pain inter-
ference, perceived pain treatment effectiveness) vary by race
and then whether opioid use moderates these associations.
These analyses are part of a retrospective cohort study among
3,505 black and 46,203 non-Hispanic, white Department of
Veterans Affairs (VA) patients with diagnoses of chronic mus-
culoskeletal pain who responded to the 2007 VA Survey of
Healthcare Experiences of Patients (SHEP). We used elec-
tronic medical record data to identify prescriptions for pharma-
cologic pain treatments in the year after diagnosis (Pain
Diagnosis index visit) and before the SHEP index visit (the
visit that made one eligible to complete the SHEP); pain out-
comes came from the SHEP. We found no significant associa-
tions between race and pain interference or perceived
effectiveness of pain treatment. VA patients with opioid pre-
scriptions between the Pain Diagnosis index visit and the
SHEP index visit reported greater pain interference on the
SHEP than those without opioid prescriptions during that
period. Opioid prescriptions were not associated with per-
ceived treatment effectiveness for most patients. Findings raise
questions about benefits of opioids for musculoskeletal pain
and point to the need for alternative treatments for addressing
chronic noncancer pain.
Key words: blacks, chronic pain, Department of Veterans
Affairs, disparities, opioids, pain outcomes, pain treatment
effectiveness, race, survey, Veterans.
INTRODUCTION
Numerous studies have shown that blacks are less
likely than whites to be prescribed opioid analgesics for a
variety of pain conditions [1]. These disparities have
been viewed as especially problematic in light of evi-
dence that blacks experience chronic pain that is more
severe and more disabling than whites [2–7]. Although
many factors contribute to these racial disparities in pain
outcomes (e.g., racial differences in patients’ beliefs
about pain [4,8–10], exposure to racial discrimination
[11–12]), there is concern about the role of undertreatment
Abbreviations: CI = confidence interval, HSR&D = Health
Services Research and Development Service, ICD-9 = Interna-
tional Classification of Diseases-9th Revision, NPCD =
National Patient Care Database, OR = odds ratio, PTSD =
posttraumatic stress disorder, SHEP = Survey of Healthcare
Experiences of Patients, VA = Department of Veterans Affairs.
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of pain [1–3,13]. Consequently, recent position papers
have highlighted the importance of reducing racial dis-
parities in opioid prescription and proposed strategies to
accomplish this goal [2–3].
There is a tension, however, between the imperative
to address racial disparities in opioid treatment and
acknowledgment of the public health crisis caused by
increased prescription of opioids, particularly in light of
incomplete evidence about their benefits relative to the
known risks. There are limited data on the long-term
effectiveness and safety of opioids for the treatment of
chronic noncancer pain [14–15] and mounting evidence
of serious risks associated with opioids [15–18].
Although there have been numerous studies documenting
racial disparities in opioid use [1], there is scant research
on whether these disparities are, in fact, associated with
poorer pain outcomes for black patients.
Our prior research found that among Department of
Veterans Affairs (VA) patients diagnosed with a chronic
musculoskeletal condition who reported moderate or
high levels of pain and who were under age 65, blacks
were less likely to be prescribed opioids than their white
counterparts [19]. The objectives of this study were to
examine whether pain outcomes (pain interference, per-
ceived pain treatment effectiveness) among those who
reported being treated for chronic pain at VA vary by race




This was a retrospective cohort study using survey
data from the 2007 VA Survey of Healthcare Experiences
of Patients (SHEP) ambulatory care module and data
extracted from the VA National Patient Care Database
(NPCD). This study was approved by the institutional
review board of the Minneapolis VA Health Care System.
Setting and Participants
We identified a retrospective cohort using the 2007
SHEP ambulatory care module, a national survey admin-
istered quarterly by the VA Office of Quality and Perfor-
mance, to solicit patient-reported information concerning
recent specific episodes of outpatient care. Each individ-
ual selected was surveyed about an episode of care
(referred to as the SHEP index visit). This survey was
mailed to patients early in the second calendar month fol-
lowing their SHEP index visit, and data collection was
closed 4 wk after the survey was mailed. We identified a
sample of patients with chronic pain (9,831 black and
71,471 white patients, referred to as the “chronic pain
sample”) using the same criteria as we used in our previ-
ous research examining racial differences in opioid pre-
scriptions in VA [19] (Figure 1). The sample included
non-Hispanic black or white established and new primary
care patients who were selected to be in the 2007 SHEP
(irrespective of whether or not they responded to the
SHEP) and met the following inclusion criteria: (1) any
diagnoses of back, neck, or joint pain in the year prior to
the SHEP index visit; (2) no cancer diagnoses in the year
prior to the SHEP index visit; and (3) no outpatient opi-
oid prescription received in the 3 mo prior to the first
pain diagnosis (Pain Diagnosis index visit). Our rationale
for restricting the sample to patients who had no opioid
prescription in the first 3 mo prior to the Pain Diagnosis
index visit was to ensure that the opioid was prescribed
for treatment of that particular pain episode rather than
for a different reason. In analyses examining pain inter-
ference as an outcome, we included only those patients
who responded to the SHEP (3,505 non-Hispanic blacks
and 46,203 non-Hispanic whites). In our analyses exam-
ining perceived treatment effectiveness as an outcome,
we further restricted our sample to those who reported on
the SHEP that they were treated for chronic pain in the
VA in the past year (1,622 non-Hispanic blacks and
13,758 non-Hispanic whites).
Study Outcomes
Pain interference was measured using the SHEP
item: “During the past 4 weeks, how much did pain inter-
fere with your normal work (including both work outside
the home and housework)?” This item is drawn from the
Bodily Pain subscale of the 36-Item Short Form Health
Survey (SF-36) [20]. Consistent with prior research [21–
22], we dichotomized responses into two categories:
(1) not at all/a little bit and (2) moderately/quite a bit/
extremely. We decided to dichotomize the pain interfer-
ence scale in order to capture the construct of functional
limitations due to pain, in which “not at all/a little bit”
represents every day aches and pains, whereas “moder-
ately/quite a bit/extremely” represents clinically action-
able pain, requiring comprehensive assessment and
treatment [23].
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Perceived effectiveness of pain treatment among
those who reported being treated for chronic pain in VA
was measured using the SHEP item: “If you have been
treated by a VA provider for chronic pain, please rate the
effectiveness of your pain treatment.” This analysis only
included those patients who reported on the SHEP that
they were treated for chronic pain in the VA in the past
year. Response options were poor, fair, good, very good,
and excellent. Previous research with Veterans has dem-
onstrated that single-item ratings of treatment effective-
ness are significantly associated with posttreatment
changes in self-reported ratings of pain severity, pain
interference, and disability [24]. Responses were dichoto-
mized into two categories: (1) poor and fair and (2) good,
very good, and excellent. Consistent with prior research
examining differences in perceived quality of care [25],
we dichotomized the perceived effectiveness scale into
“poor” and “fair” versus “good,” “very good,” and
“excellent” in order to capture whether patients perceived
their chronic pain treatment as ineffective versus effective.
Primary Predictors
Patient race was obtained from the SHEP (i.e., sur-
vey self-report) and supplemented with administrative
data from the NPCD when missing. The SHEP race and
ethnicity measures were used to derive two categories:
non-Hispanic white and non-Hispanic black.
Figure 1.
Samples used to test specific hypotheses. SHEP = Survey of Healthcare Experiences of Patients, VA = Department of Veterans
Affairs.
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Receipt of any opioid prescription was defined as an
outpatient prescription of any opioid for any duration
issued by a VA pharmacy between the Pain Diagnosis
index visit and the SHEP index visit (Figure 2) obtained
from the NPCD. The mean ± standard deviation time
period between the Pain Diagnosis index visit and the
SHEP index visit was 163 ± 134 d.
Demographic and Clinical Covariates
Sex and age were obtained from the NPCD. Marital
status was obtained from the SHEP and supplemented
with NPCD data. We used the NPCD to obtain Interna-
tional Classification of Diseases-9th Revision (ICD-9)
diagnostic codes from outpatient visits to determine
whether patients had diagnoses of medical and mental
health comorbidities, including prior pain-related diagno-
ses (i.e., neck, back, or joint pain); opioid use disorder; or
other substance use disorder during the year prior to the
first pain-related diagnosis using the same codes as were
used in the TROUP (Trends and Risks of Opioid Use for
Pain) Study [26]. ICD-9 codes were also used to identify
30 comorbidity measures developed by Elixhauser and
colleagues for use with large administrative data sets
[27]. Additional diagnoses (separate from Elixhauser
measures) hypothesized to be associated with pain out-
comes or pain treatment: phantom limb pain, psycho-
genic pain, spinal cord injury, and posttraumatic stress
disorder (PTSD) were included in analyses (see Burgess
et al. for diagnosis codes [19]).
VA guidelines recommend screening for the presence
and intensity of pain at each outpatient visit using a
numerical 0 (no pain) to 10 (worst pain imaginable) rat-
ing scale. In our analysis, we used the pain intensity rat-
ing that occurred at the Pain Diagnosis index visit if it
was documented in the NPCD. If there was no docu-
mented pain intensity rating at the Pain Diagnosis index
visit, we used the documented pain intensity rating at the
most proximal time prior to the Pain Diagnosis index
visit. We categorized pain intensity ratings using standard
cutpoints indicating no pain (0), mild pain intensity (rat-
ings of 1–3), moderate pain intensity (ratings of 4–6), and
severe pain intensity (ratings of 7–10) [28–29].
Figure 2.
Temporal structure of data. Dx = diagnosis, SHEP = Survey of Healthcare Experiences of Patients.
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Healthcare utilization in the year prior to the first pain
diagnosis was summarized using the number of outpatient
visits and inpatient admissions from NPCD data. We
obtained information about whether the patient was clas-
sified as new to primary care versus established (i.e., pre-
vious primary care visit(s)) from the SHEP, as the
likelihood of receiving an opioid may be greater among
established patients.
Statistical Analyses
We fit a hierarchical logistic regression model for
good to excellent effectiveness of pain treatment among
the members of the cohort who responded to the per-
ceived effectiveness SHEP item and who reported being
treated for chronic pain at the VA within the past year.
We investigated whether race was associated with the
effectiveness of treatment and, subsequently, whether
opioid use moderated any association between race and
treatment effectiveness. As our analyses found that the
likelihood of receiving opioids varied with prior pain
intensity level, we stratified these analyses by prior pain
intensity ratings. Within each subgroup (no, mild, moder-
ate, and severe pain), we fit a generalized linear mixed
logistic regression model incorporating fixed effects for
race (black or white), new or established primary care
patient, receipt of opioids between the Pain Diagnosis
index visit and the SHEP index visit, days between the
Pain Diagnosis index visit and the SHEP index visit, and
an interaction between race and receipt of opioids com-
bined with the demographic, utilization, prior pain diag-
noses, and comorbidity measures discussed previously.
Comorbidity measures were included as covariates if
there was a 5 percent or greater difference in treatment
rates among those with and without the comorbidity and
at least 100 members of the cohort were diagnosed with
the condition. The model incorporated (Gaussian) ran-
dom intercepts for each facility and (Gaussian) random
race effects for each facility to allow for race differences
to vary by facility and also allow us examine overall race
differences through the estimated fixed effects for race.
These generalized linear mixed models were imple-
mented using pseudo-likelihood algorithms in PROC
GLIMMIX, SAS, version 9.2 (SAS Institute Inc; Cary,
North Carolina).
The same process was used to investigate the associ-
ation between race and perceived effectiveness of chronic
pain treatment and whether opioid use moderated the
association between race and perceived effectiveness. We
conducted this analysis among the members of the cohort
who responded to the perceived effectiveness SHEP item
and who reported being treated for chronic pain at the VA
within the past year.
Response to the SHEP was incomplete (61% of our
chronic pain sample responded to the SHEP). To assess
the potential effect of survey nonresponse on the study
findings, we fit a logistic regression for SHEP response
using those demographic, medical and mental health
comorbidities, and healthcare utilization measures that
differed between responders and nonresponders as pre-
dictors. We estimated the propensity for responding to
the SHEP from this model, formed eight strata from these
estimated propensities, and verified that responders and
nonresponders were well balanced within these strata.
We then included this strata variable in the models (as an
additional predictor) [30].
RESULTS
Sample Characteristics by Race
Black patients were more likely to be female and
unmarried, more likely to have diagnoses of back and
neck pain, and less likely to have a diagnosis of joint
pain. Black patients were also more likely than white
patients to have diagnoses of opioid use disorder, alcohol
or drug use disorders, or a psychiatric disorder, including
PTSD. (See Table 1 for tests of statistical significance.)
Pain Interference
Pain interference was not associated with race for
any level of pain intensity rating (pain intensity rating 0,
p = 0.17; 1–3, p = 0.54; 4–6, p = 0.93; and 7–10, p =
0.98). Opioid use did not moderate the association
between race and pain interference for any level of pain
(pain intensity rating 0, p = 0.59; 1–3, p = 0.41; 4–6, p =
0.51; and 7–10, p = 0.74).
Pain interference was significantly higher for those
who received an opioid prescription. The association
between pain interference and opioid prescription was
stronger for patients with lower pain intensity ratings: 0
(odds ratio [OR] = 1.94, 95% confidence interval [CI] =
1.71–2.19, p < 0.001), 1–3 (OR = 1.84, 95% CI = 1.50–
2.25, p < 0.001), 4–6 (OR = 1.70, 95% CI = 1.42–2.04, p <
0.001); and 7–10 (OR = 1.45, 95% CI = 1.21–1.75, p <
0.001). Table 2 presents observed and estimated prevalence
ratings of pain interference for black and white patients
who were and were not prescribed opioids, stratified by
prior pain intensity ratings.
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Table 1.
Association between patient race and demographic, health-related, and utilization characteristics. Data presented as percentage or mean ±
standard deviation.
Characteristic White (n = 46,203) Black (n = 3,505) p-Value
Established Patient (vs new) 63.47 59.86 <0.001
Demographics
Male 95.44 90.04 <0.001
Married 68.55 48.91 <0.001
Age (yr) 68.04 ± 12.31 58.63 ± 12.80 <0.001
Physical and Mental Health
Chronic Back Pain 26.31 30.41 <0.001
Chronic Neck Pain 4.60 5.93 <0.001
Chronic Joint Pain 77.87 74.12 <0.001
Cardiac Arrhythmias 10.08 4.48 <0.001
Chronic Heart Failure 4.28 2.82 <0.001
Chronic Pulmonary Disease 14.66 10.33 <0.001
Diabetes (uncomplicated) 21.31 23.08 0.01
Fluid and Electrolyte Disorders 1.99 2.80 0.001
Liver Disease 1.26 3.14 <0.001
Renal Failure 3.27 4.08 0.01
Sleep Apnea 3.97 4.51 0.12
Headache 2.96 5.42 <0.001
Inflammatory Bowel Disease 0.52 0.57 0.69
Neuropathy 6.35 6.62 0.53
Opioid Use Disorder 2.81 6.99 <0.001
Alcohol/Drug Use Disorder 4.34 10.13 <0.001
Depression 14.97 19.63 <0.001
Psychosis 1.32 3.05 <0.001
PTSD 5.02 9.33 <0.001
Other Mental Health Disorders 20.48 25.34 <0.001
Mean No. Outpatient Visits 16.12 ± 17.25 20.89 ± 23.82 <0.001
Mean No. Inpatient Admissions 0.05 ± 0.30 0.07 ± 0.39 <0.001
No. = number, PTSD = posttraumatic stress disorder.
Table 2.




Yes Opioids No Opioids
Whites Blacks Whites Blacks
Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI
0, No Pain 1,556 (70.8) 79.8 74.6–84.2 132 (77.7) 83.3 75.2–89.2 24,184 (46.9) 67.4 60.8–73.3 1,465 (55.8) 69.6 63.1–75.4
1–3, Mild 702 (77.7) 87.2 80.0–92.2 38 (86.1) 90.9 77.0–96.7 6,352 (60.3) 79.0 68.6–86.7 387 (63.0) 78.1 67.1–86.2
4–6, Moderate 1,137 (84.0) 91.0 85.5–95.0 114 (87.4) 92.0 84.5–96.1 6,773 (72.0) 86.0 78.0–91.4 615 (73.6) 84.8 76.4–90.6
7–10, Severe 1,315 (85.5) 93.1 87.0–96.4 179 (86.9) 93.4 86.5–96.9 4,184 (78.3) 90.0 82.0–95.0 575 (82.8) 90.0 82.0–94.8
Note: degrees of freedom = 46,407.
*Calculated at typical facility with covariates (demographics, utilization, prior pain diagnoses, and comorbidities) at modal/mean values.
CI = confidence interval, Est = estimated, Obs = observed.
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Perceived Effectiveness of Pain Treatment
Perceived effectiveness of pain treatment was not
associated with race (pain intensity rating 0, p = 0.24; 1–
3, p = 0.06; 4–6, p = 0.37; and 7–10, p = 0.78). Opioid
use did not moderate the association between race and
perceived effectiveness of pain treatment (pain intensity
rating 0, p = 0.71; 4–6, p = 0.70; and 7–10, p = 0.15),
except among patients with mild pain intensity ratings
(1–3, p = 0.008); however, this is difficult to interpret
because of the small cell size of black patients in this cat-
egory (n = 24). The main effect of opioid prescription
was not significant, with the exception of the mild pain
intensity group (pain intensity rating 0, p = 0.13; 1–3, p =
0.003; 4–6, p = 0.77; and 7–10, p = 0.37). Table 3 pres-
ents observed and estimated prevalence ratings of per-
ceived effectiveness of pain treatment for black and
white patients who were and were not prescribed opioids.
DISCUSSION
Among VA primary care patients with a chronic non-
cancer pain diagnosis, race was not associated with pain
interference or with perceived treatment effectiveness.
Moreover, among black and white VA patients, receipt of
an opioid prescription was significantly associated with
greater pain interference and was not significantly associ-
ated with perceived treatment effectiveness, except for
individuals with mild pain. The results do not vary signif-
icantly by age group. Hence, our prior findings of lower
rates of opioid prescriptions among blacks than whites
younger than 65 yr did not appear to contribute to racial
differences in pain outcomes [19].
To our knowledge, this is the only study to examine
associations of racial disparities in opioid prescriptions
on clinically relevant pain outcomes among chronic pain
patients and one of the first to examine the effectiveness
of opioid therapy in a large integrated healthcare system.
Understanding the effect of racial disparities in opioid
prescription is particularly important in light of mounting
evidence of serious risks associated with opioids [15–18],
the rapid increase in opioid prescription for chronic non-
cancer pain over the last 10–15 yr, and the lack of evi-
dence on the long-term effectiveness and safety of
opioids for this purpose [14–15].
Our findings raise the broader question of whether
efforts to address racial disparities in pain should focus
on reducing disparities in opioid prescription, as has been
suggested in prior policy recommendations [3]—at least
in the case of patients with chronic noncancer pain. The
use of race in decisions to prescribe opioids is clearly
inconsistent with good medical practice and arguably
constitutes racial bias. Although our results should be
considered preliminary because of our retrospective
cohort study design, which precludes the ability to draw
causal inferences about the effect of opioid prescription
on pain outcomes, the high levels of pain interference
among the majority of black and white patients with prior
opioid prescriptions suggests that additional treatment
modalities may be needed for patients with chronic noncan-
cer pain. Indeed, there is growing consensus that chronic
noncancer pain is best addressed by a biopsychosocial
approach that acknowledges the role of psychological
and environmental factors in pain [31], some of which
differ by race and hence contribute to worse pain among
blacks. For example, blacks experience greater pain-
related fear and lower self-efficacy in coping with pain
[4,8–10]. Blacks are more likely to reside in neighbor-
hoods that make engaging in physical activity difficult
[32–33]. Blacks are also more likely to be exposed to
Table 3.
Observed and estimated prevalence* of perceived effectiveness of pain treatment among black and white Veterans with and without opioid
prescriptions who reported being treated at Department of Veterans Affairs for chronic pain.
Pain Intensity
Yes Opioids No Opioids
Whites Blacks Whites Blacks
Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI Obs n (%) Est (%) 95% CI
0, No Pain 850 (62.7) 56.7 43.3–69.2 89 (58.1) 53.9 38.0–69.0 4,396 (66.5) 60.0 46.4–72.1 488 (59.1) 54.8 41.6–67.3
1–3, Mild 439 (67.5) 52.8 33.1–71.6 24 (37.5) 26.5 10.6–52.3 1,850 (62.4) 41.1 23.2–61.6 161 (61.4) 45.2 26.1–65.7
4–6, Moderate 764 (55.9) 62.4 47.1–75.6 82 (58.4) 66.8 49.2–80.7 2,637 (56.4) 62.1 46.3–75.6 316 (54.7) 63.9 48.3–77.0
7–10, Severe 917 (52.4) 46.0 30.3–62.5 126 (56.5) 51.3 33.9–68.4 1,905 (53.2) 45.2 29.1–62.4 336 (47.9) 42.0 26.6–58.6
Note: degrees of freedom = 15,307.
*Calculated at typical facility with covariates (demographics, utilization, prior pain diagnoses, and comorbidities) at modal/mean values.
CI = confidence interval, Est = estimated, Obs = observed.
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discrimination, which has been shown to contribute to a
more severe pain experience [11].
It is notable that black and white patients did not sig-
nificantly differ in their perceptions of chronic pain treat-
ment effectiveness or in their reported pain interference
in our adjusted analyses. At first glance, these results
seem inconsistent with the large body of literature docu-
menting racial disparities in pain care and treatment
[2,4]. However, most of the literature describing racial
disparities in treatment (including several studies con-
ducted at the VA prior to the present study [20,34–37])
examines specific types of treatment (e.g., opioid ther-
apy, pain-relieving surgical procedures) rather than
patients’ evaluations of their overall quality of pain treat-
ment. An exception is Dobscha et al. who, using data
from the 2005 SHEP, found that black men perceived
their pain treatment to be less effective than white men,
after controlling for demographics, pain, and mental
health comorbidities [20]. It is unclear whether discrep-
ancy between the present findings and those of Dobscha
et al. are due to methodological differences between the
two studies or the fact that our study used data collected
at a later time point, in which pain care quality in VA
could have conceivably improved.
There are a number of limitations to this study and
remaining questions that require additional research to
address. Because we examined only VA outpatients,
these results may not generalize to patients in other
healthcare systems that have fewer processes and struc-
tures to support effective pain management. In addition,
many improvements in pain management were imple-
mented subsequent to when these data were collected in
2007. We also used self-reported measures of pain out-
comes, which consisted of two single-item survey ques-
tions. It should be noted that the use of subjective
measures of pain outcomes is consistent with standards
of pain treatment, which emphasize the subjective nature
of pain and stress the importance of the patient’s experi-
ence of whether his or her pain is adequately relieved
[13]. There is consensus that patients’ satisfaction with
care is an important measure of healthcare quality, and
evidence that patient satisfaction is associated with
important outcomes such as health status, health-related
quality of life, and medication adherence [38–40]. How-
ever, future studies should use more comprehensive mea-
sures of pain outcomes, such as those recommended by
the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) [29]. A
related limitation is our use of a single pain intensity
score to stratify the sample rather than use of multiple
pain scores or a multidimensional measure of pain.
Another potential limitation is that we restricted our sam-
ple to patients who did not have an opioid prescription
during the 3 mo prior to their Pain Diagnosis index visit.
We made this decision to ensure that the opioid prescrip-
tion was for treatment of that particular chronic pain epi-
sode rather than for some other indication. Nonetheless,
it is possible that this requirement (that people with pain
have an opioid-free period) could limit the generalizabil-
ity of these conclusions. Additionally, because our defini-
tion of opioid use included all patients who received
opioid prescriptions any time during the period between
the Pain Diagnosis index visit and the SHEP index visit,
regardless of duration of prescription or indication, some
patients might not have been taking an opioid at the time
they had their pain intensity assessed. As a result, our
conclusions should be interpreted with caution.
It is also unclear why the association between pain
interference and opioid use was stronger among patients
with lower pain intensity ratings. While opioids may
reduce pain, there is also evidence that they can impair
function [15,41]. It is possible that patients with lower
pain intensity on opioids experienced greater pain relief
at the cost of poorer functioning. Another possible expla-
nation is that opioids may have analgesic benefits with-
out improving functioning or reducing pain interference.
This might be particularly true for patients who received
opioids short-term for acute pain or for temporary exac-
erbations of chronic pain (i.e., “pain flares”) without
improving their overall perceptions of functioning or
pain interference at the time the SHEP was completed.
Future research is required to address this question,
which cannot be answered by our study design, as it pre-
cludes the ability to draw causal inferences about the
effect of opioid prescription on pain outcomes. Patients
who received opioids may also have had worse disease
severity or prognosis, and this underlying disease rather
than opioids (or in conjunction with the opioids) may be
contributing to the outcomes assessed. We also are not
certain why perceived effectiveness was lower among
individuals with mild chronic pain than those with mod-
erate pain. It is possible that pain may be less of a clinical
concern among those with lower levels of pain and,
therefore, may not be addressed as much by their provid-
ers. Consequently, such patients may perceive their pain
care to be less effective relative to those with greater
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pain, whose providers may be doing more to address
their pain. Future research is needed to address this novel
finding. We are also unsure why so many patients
received pain intensity ratings of 0 at the clinic visit in
which they were given a pain diagnosis. One possibility
is that patients were not asked about their pain, but the
healthcare professional entered a 0 anyway. Other possi-
bilities are that some disorders that might be presumed to
be painful may not be persistently painful (e.g., osteoar-
thritis) or that pain may be absent when the patient is
asked while seated comfortably when other vitals are
being taken (e.g., in the case of low back pain or other
degenerative disorders).
Several implications for research, policy, and prac-
tice flow from this work. First, randomized controlled tri-
als that include a sufficient number of black patients are
clearly needed to fill literature gaps about the appropri-
ateness of opioids for chronic noncancer pain. Moreover,
the high prevalence of black and white patients who
reported substantial pain interference and who perceived
their pain treatment as ineffective points to the need to
improve the quality of chronic pain treatment available in
primary care, where the majority of pain treatment in the
VA (and the United States) occurs. Unfortunately, studies
conducted in various settings, including the VA, have
shown that primary care providers find chronic pain
patients to be frustrating and difficult to treat and do not
feel adequately prepared to provide care for them [42–
43]. The growing movement toward “patient-centered
medical homes,” which are based on principles of acces-
sibility, continuity, and care coordination, provides an
opportunity for more effective and equitable chronic pain
care [3,44]. However, because these models center on the
role of primary care providers, it is critical that these pro-
viders have training in chronic pain treatment overall and
in providing equitable care [3]. Such training should also
ensure that providers are aware of nonopioid-based treat-
ments for chronic pain and be familiar with the biopsy-
chosocial model of chronic pain that acknowledges the
role of psychological and environmental factors in pain
[45]. One promising approach is the VA’s Stepped Care
Model of Pain Management, in which pain is managed
by primary care providers, with support from mental
health and specialty services as needed, and which is
explicitly designed to promote equitable access to care
[46]. A recent evaluation of this program has documented
a reduction in referrals to pain medicine specialists, signify-
ing primary care providers’ greater confidence in treating
chronic pain, as well as a reduction in the proportion of
patients receiving high-dose opioids and an increase in
referrals to physical therapy and chiropractic care [47].
Although more research is needed, this program and
other collaborative care approaches to pain management
[48] point to the utility of this approach for improving the
quality and equity of treatment for chronic pain.
CONCLUSIONS
In our retrospective cohort study examining VA pri-
mary care patients with a chronic noncancer pain diagno-
sis, receipt of an opioid prescription was associated with
greater pain interference and was not associated with per-
ceived treatment effectiveness for most patients. Findings
raise questions about benefits of opioids for musculoskel-
etal pain and point to the need for alternative treatments
for addressing chronic noncancer pain.
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